Qualifications

  • LL.B. (Hons), National University of Singapore
  • Admitted to the Singapore Bar (1992)

Tony is the Managing Director of our Intellectual Property department, and a Director in our Dispute Resolution department. He also heads our Healthcare & Life Sciences Practice. Tony is currently representing leading biotech and pharmaceutical companies such as Sanofi-Aventis and Novartis; government statutory boards such as Sentosa Development Corporation, and Health Promotion Board; as well as listed companies such as PT Bayan Resources Tbk and Manhattan Resources Ltd.

Tony is a litigator with an active court practice as an advocate. He has acted as lead counsel in many complex matters, including numerous patent infringement cases. He is experienced in intellectual property litigation and enforcement including patent, trade mark, and copyright litigation. His civil and commercial litigation practice includes banking litigation and contract disputes.

Tony was appointed by the Intellectual Property Office of Singapore (IPOS) as an IP Adjudicator to hear disputes at IPOS for a two-year term from April 2019. He is also the President of the International Association for the Protection of Intellectual Property (AIPPI) – Singapore Group, a member of the Law Society’s Inquiry Committee and Disciplinary Tribunal, and a member of the Examination Board at IPOS for registered patent agents.

He also co-authored the Singapore chapter of Global Pharmacovigilance Laws & Regulations: The Essential Reference, which has been described as a “groundbreaking book” and a “landmark guide” published by the US based Food and Drug Law Institute. Tony also co-wrote the article “Legislating medical devices in Singapore” in Financier Worldwide: Biotechnology & Life Sciences e-Book 2010.

Under his guidance and leadership, Drew & Napier clinched double wins at the 2018 Asia IP Awards, winning both the Singapore Trade Mark Firm of the Year and the Singapore Patent Firm accolades.

Tony has been involved in many high profile matters. Here are just a few recent cases:

  1. Acted as an IP Adjudicator at the Intellectual Property Office of Singapore to hear a significant Trade Mark matter involving two well-known watchmakers. In Rolex S.A. v FMTM Distribution Ltd [2020] SGIPOS 6, Rolex S.A’s opposition against an Application Mark filed by the Franck Mueller Group was allowed on grounds of confusing similarity and passing off under the Trade Marks Act. As the opposition was successful, registration of the Application Mark was refused.

  2. Representing IIa Technologies Pte Ltd, an industry leader in state-of-the-art lab grown diamond technology, in a patent infringement suit commenced by Element Six Technologies Ltd, a subsidiary of the De Beers Group, in HC/Suit No. 26/2016, including a counterclaim by IIa Technologies Pte Ltd to revoke Element Six Technologies Ltd’s patents in the Singapore High Court.

  3. Acting as lead counsel for Tanaka Electronics Singapore (Pte.) Ltd. in the Singapore High Court patent infringement action, which is the latest development in the ongoing global patent litigation dispute with Nippon Steel Chemical & Material Co., Ltd. and Nippon Micrometal Corporation. Tanaka Electronic Singapore (Pte.) Ltd. owns a manufacturing facility in Singapore manufacturing bonding wires for semiconductors. Nippon Steel has alleged that Tanaka Electronics Singapore (Pte.) Ltd. has infringed Singapore Patent No.  2010038305 and has prayed for, amongst others, an injunction.  Tanaka Electronic Singapore (Pte.) Ltd. has denied infringement and has put in issue the validity of the asserted patent claims.

  4. Currently advising a client in a potential arbitration action before the International Chamber of Commerce involving the sale of advanced technology equipment.

  5. Representing Golden Village Multiplex Pte Ltd (“Golden Village”), Singapore’s leading cinema operator, in HC/S 1155/2019, in a suit commenced by Composers and Authors Society of Singapore Limited (“COMPASS”) in relation to the payment of royalties for the public performance of musical works in the films screened at Golden Village’s cinemas. The suit includes a counterclaim by Golden Village for breach of contract and misrepresentation by COMPASS.

Chambers Asia-Pacific

Intellectual Property 2021 – Band 1 for 3 consecutive years

Band 2 (2009 to 2018)

“Tony is an esteemed practitioner who frequently represents clients in IP litigation at the appellate stages. He has experience working on royalties disputes, advising a range of domestic and multinational clients.”

Sources say that “You can take comfort knowing that Tony is at the wheel when driving forward your litigation in unchartered legal landscapes"

Tony is "a seasoned patent litigator".

“He quickly understands complex IP issues and is able to convey them in a way that is easy to understand,” adding: “He understands the client's needs and delivers results that meet the company's strategy and goals. He is also very creative and thinks outside the box.”

He is extremely hands-on, clear in his thinking, has foresight and draws a lot of perspective from his past experience to evaluate the next steps,"

"...with Tony we are well informed, and he always walks in with a sound plan which makes it easy to make an informed decision.”

"[Tony] leverages on his strong healthcare and life sciences sector expertise and regularly acts for major pharmaceutical clients in notable patent infringement disputes."

"A highly reputed litigator in the IP practice who is described as both "hugely enthusiastic" and "very commercial.""

“A very confident individual who always stays on top of the situation."

Managing Intellectual Property
Voted an IP Star 2020 for 7 consecutive years – Patent litigation, Patent prosecution, Trade mark litigation, Trade mark prosecution

“Tony is responsive, quick thinking and highly practical in his advice.”

“First class service and quality work”

Tony [Yeo] is charming, knowledgeable, and has a knack of explaining things simply and in the context of the overall strategy. He is an effective litigator and is incisive in cross-examinations."

The Asia Pacific Legal 500
Intellectual Property 2021 – Hall of Fame for 2 consecutive years
Intellectual Property 2020 – Leading individual for 10 consecutive years

Dispute Resolution 2018 – Recommended lawyer

“Tony Yeo is sharp and appropriately aggressive lawyer whom you will want on your side. Possessing good commercial sense and great depth of knowledge as subject matter experts, he will be able to value-add by strategising approaches for the best outcomes. First-class lawyer.’

“Tony Yeo is an absolutely first-class litigator. Amazing in the court room. He is not only able to provide high-level strategic advice, but is able to also zoom in and pick up on the minute details. Great depth of knowledge.

Sources say that Tony is “a fantastic strategist and a great litigator”

“Diligent, sound in judgment and pragmatic in approach”

“One of the foremost lawyers in Drew & Napier’s excellent litigation practice with in-depth knowledge of IP-related issues”

Asialaw Leading Lawyers
Intellectual Property 2021 - Elite Practitioner for 4 consecutive years

Tony Yeo is recommended by his client for his “great depth of knowledge. Very savvy. Fantastic litigator.”

Dispute Resolution 2018 – Market-Leading Lawyer for 2 consecutive years

Client feedback (2017): “Market-leading lawyer Tony Yeo’s “strategic thinking, honesty and timely responsiveness”… (is) prized by clients.”

Who’s Who Legal
Life Sciences - Patent Litigation 2021 – Global Elite Thought Leader

Life Sciences 2020  
Leading Lawyer for 10 consecutive years
Global Elite Thought Leader - Patent Litigation 2020 
Recommended Lawyer for Product Liability and Regulatory - Life Sciences 2020 

Tony Yeo of Drew & Napier is as “seasoned litigator” who “stands out among the pack”.

Clients commend him for being “highly engaged and hardworking” and for always “focusing on the best interest of clients”

“Tony Yeo is recommended across our life sciences chapters for his wide-ranging expertise in the area.”

Patents 2020 – Leading Lawyer for 7 consecutive years

Trademarks 2020 – Leading Lawyer for 4 consecutive years

Clients say Tony is a “formidable litigator” who is “extremely knowledgeable in IP matters”. He impresses with his “ability to balance commercial considerations with effective legal strategies”.

Tony Yeo of Drew & Napier is “an extremely skilled litigator and strategist” who impresses clients with “his depth of knowledge of the subject matter”.

Benchmark Litigation Asia-Pacific

Litigation Star in Dispute Resolution and Intellectual Property (2020)

Dispute Resolution Star in Intellectual Property (2019)

Clients say: “Tony is responsive, commercially aware and a skilled advocate”

World Trade Mark Review 1000
Enforcement and Litigation 2020 – Recommended individual for 3 consecutive years 

Tony Yeo is a “first-rate litigator who navigates clients through the minefields of IP management without a hitch”

Sources commend Tony’s “efficient delivery” of “well-informed” strategies.

IAM Patent 1000
Ranked gold band in litigation in 2020

The shining gem in the ensemble is Tony Yeo. “One of the most respected litigators in town”, the star player recently joined other distinguished IP legal experts on the IPOS IP Adjudicators Panel.

“Tony [is] the attorney to have on speed dial when a complex IP issue arises and you want pragmatic legal advice.”

“Managing director of intellectual property Tony Yeo is most at home when resolving intricate patent disputes on behalf of major clients in the healthcare and life sciences arenas. Renowned for his silver-tongued advocacy, Yeo is a master of cross-border and technically advanced patent infringement suits.”

“Famed for its strength in disputes, the firm boasts no shortage of star litigators – and Tony Yeo stands out among them. A courtroom sharpshooter with over 25 years’ experience in patent litigation…”

Life sciences captain Tony Yeo “keeps competitors on their toes” in hotly contested disputes between big pharma combatants.

“Clients adore the highly intelligent Tony Yeo; his facility for grasping the technicalities of a case means that he always quickly addresses the real problem.”

[Tony Yeo] is “bright and extremely easy to work with. He has a good instinct for the right answer and always provides sensible and pragmatic advice”.

IAM Global Leaders 2021 edition
Identified as one of Singapore’s foremost patent experts

World IP Review 
Identified as a leading practitioner in IP in 2017

Asia IP Experts 2018
Listed as a leading individual for 3 consecutive years in IP Enforcement, Patents, and Litigation

Listed as a leading individual in Pharma & Biotech for 6 consecutive years

ILO Client Choice Awards
Winner of the Singapore Healthcare & Life Sciences Award 2013

Asian Legal Business
Ranked among other lawyers in ALB’s Hot 100

  • President, International Association for the Protection of Intellectual Property (AIPPI) Singapore Group
  • IP Adjudicator at the Intellectual Property Office of Singapore (IPOS) from April 2019 for a two-year term
  • Assessor, Panel of Assessors for COVID-19 Temporary Relief, Ministry of Law
  • Honorary legal counsel, Orchard Road Business Association (ORBA)
  • Honorary legal counsel, Singapore Advertisers Association
  • Member, Singapore Patent Agents Examination Board at the IPOS
  • Member, Accounting and Corporate Regulatory Authority (ACRA) Disciplinary Committee
  • Member, Supreme Court Pleadings Precedent Selection Committee - Intellectual Property
  • Member, Law Society’s Inquiry Panel and Disciplinary Tribunal
  • Member, Asian Patent Attorneys Association
  • Member, International Trademark Association
  • The Singapore chapter of Life Sciences, Lexology Getting the Deal Through, 2021
  • The Singapore chapter of Patent Litigation Country Comparative Guide, The Legal 500, 2020
  • The Singapore chapter of Life Sciences, Getting the Deal Through, 2014, 2015, 2016, 2017 and 2020
  • “Life Sciences Jurisdictional Guide to Singapore” in Practical Law Company Multi-Jurisdictional Guide 2013, 2014, 2015, 2016 and 2017
  • “Developments in Singapore’s Healthcare Regulatory Landscape” in Asian Legal Business November 2013
  • The Singapore chapter of “Global Pharmacovigilance Laws & Regulations: The Essential Reference” published by the Food & Drug Law Institute, which has been described as a “groundbreaking book” and a “landmark guide”
  • “Legislating medical devices in Singapore” in Financier Worldwide: Biotechnology & Life Sciences e-Book 2010